We’ve ranted about the encroachment of hospital and health system owned specialty pharmacies more times that one can count. The growth of these organizations seemed
Last week the FDA approved a new specialty therapy, Jemperli (dostarlimab) from GlaxoSmithKline, for treating patients with recurrent or advanced endometrial cancer. Uterine cancers are
The article below details a new PSAO option for pharmacies, the ‘first’ PSAO for community-based specialty pharmacies from AmerisourceBergen named the Accelerate Specialty Network. Network
White bagging is back in the news and is increasingly being used by hospitals and health systems as a weapon to demonize emerging models for
So, when was the last time your company looked at its protocols to safeguard Protected Health Information (PHI)? You know, all that patient-specific information that
So, can you easily explain the differences between a chemically synthesized drug and a biologic?You might be surprised how difficult that has become. The article
We dog eared the article below some time ago but never got around to including it in a weekly Anton Rx Report. It is insightful
Patients on complex specialty therapies always have lots of questions. Lately they have been asking lots of questions about the Covid-19 vaccines and whether they
Curiouser and curiouser…….The pharmacy management rabbit hole seems to be getting curiouser by the day. The article below details a very new and provocative tactic
Specialty pharmacies won’t be dispensing Abecma (idecabtagene vicleucel), approved by the FDA last week. Abecma is an INFUSED cell-based gene therapy to treat adult patients
